Business Wire

AFFISE

24.2.2021 14:02:11 CET | Business Wire | Press release

Share
Affise Raises $8M Series A to Make Partnerships a Measurable and Transparent Marketing Channel

Affise , the global technology leader in partnerships management and automation, today announced a Series A funding round worth $8 million. This recent funding round, led by Leta Capital and TMT Investments, follows a period of impressive growth for the company. Founded in Vilnius, Lithuania in 2016, Affise has doubled its revenue every year and now employs over 120 professionals in six offices around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005005/en/

“Affise has shown remarkable international growth, which we are happy to intensify even further with the investment round,” said Alexander Chachava, Managing partner at Leta Capital. “We can see that performance marketing becomes essential across many new channels which were difficult to measure until recently. The company empowers its clients with the real tools to boost the business, and we believe that Affise is going to become an industry-standard in performance marketing automation software.”

“The funding round will help the team focus on geographic expansion in regions where advertising, affiliate marketing and economy as a whole are growing, namely the States and Asian countries. With such a great team and product, we believe in success,” - commented Artyom Inyutin, Co-founder & Head of Investments, TMT Investments.

As the partnership marketing industry continues an impressive growth of 10%, every year, its 2021 value is estimated to reach $1.2B. Affise endeavours to utilize the funding to expand its product suite, providing marketers with a single platform to automate and scale partnerships. Following a tremendous success entering the Chinese market in 2019, Affise plans to increase its presence in North America, LatAm, and SEA, as well as cement its leadership in Europe, Israel and India.

“Partnerships management is becoming the vital component of the marketing technology stack, and Affise has established itself as a leader in this fast-growing category,” said Stanislau Litvinau, CEO and Co-Founder, Affise. “Our commitment to representing the marketers’ interests has gained the trust of the leading agencies and networks, and we see significant potential to capture additional opportunity in the market. One strategy we’re aiming to complete with this funding is entering the adjacent market of direct advertisers and brands, empowering them to grow their marketing channel with affiliate programs”.

Affise works with over 1,000 customers, including leading brands and agencies such as Wargaming, Xapads, Hypercentage, Kismia, Mobavenue, Zorka.Mobi, Mobligent. The company boasts connections to a conglomerate of over 300,000 partners, which accelerates business growth. The winner of 14 awards in the last year alone, Affise has been crowned the leader in three categories by G2: Partner Management, Marketing Analytics, and Digital Analytics.

“The market evolution from traditional affiliates to new performance channels (influencers, brand-to-brand and other), along with the skyrocketing growth in e-Commerce in 2020, will encourage more small and medium advertisers to launch their affiliate programs'' - Dmitrii Zotov, CTO and Co-Founder, Affise. “This trend will generate demand for technological solutions to start and manage affiliate programs from scratch and achieve incremental growth. Thus, this funding round will enable us to follow Affise’s mission of empowering marketers with the tools needed to catapult their success and make accurate strategic decisions. This will drive innovations and transparency across the industry”.

About Affise

Affise is a partnership marketing platform for brands, advertisers and agencies to automate and scale their partner relations via all possible performance marketing channels: traditional affiliates, influencers, networks and agencies. The synergy of technology and the long standing experience allows Affise’s clients to make partnerships manageable and revenue predictable marketing channel. To learn more, visit www.affise.com .

Social Media:

https://www.facebook.com/getaffise

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 14:23:00 CEST | Press release

The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, w

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 14:01:00 CEST | Press release

AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trialsRubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View

NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 14:00:00 CEST | Press release

New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infr

Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 13:44:00 CEST | Press release

Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 202616.9.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye